Bangavax receives first-phase clinical trial approval from DGDA

Bangavax, a Covid-19 vaccine developed by Globe Biotech Limited, has been given the go-ahead to start phase one of its clinical trials by the Directorate General of Drug Administration (DGDA).

On Sunday, UNB received confirmation from Salahuddin, the deputy director of the DGDA.

  Learn about the COVID-19 pandemic from News Hour  

The Bangabandhu Sheikh Mujib Medical University Hospital will host the trial (BSMMU). The lead researcher of this investigation is Mamun Al Mahtab, professor of hepatology at BSMMU.

According to the DGDA letter transmitting the decision to Mamun, the study protocol is approved for a duration of one year from the date of approval by the DGDA.

In addition to the United States, Canada, Japan, India, China, South Korea, Thailand, and Vietnam, Bangladesh now joins the select group of nine nations with the ability to produce mRNA vaccines.

According to Globe Biotech Limited, Bangavax is 100% effective against all 11 Covid-19 variations, including the Delta form.

Follow News Hour

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments